U.S. Chamber Responds to Foreign Price Control Proposals on Medicare Treatments

WASHINGTON - Neil Bradley, executive vice president, chief policy officer, and head of strategic advocacy at the U.S. Chamber of Commerce, issued the following statement regarding recent proposals that would impose foreign-country reference pricing on certain Medicare medicines:

"Importing foreign price controls into the U.S. healthcare system would harm patients by limiting access to new, life-saving medicines and reducing their choices. The Chamber has long opposed price controls, which stifle innovation and jeopardize the economic contributions of the life sciences sector. Such policies threaten to undermine the $500 billion life science companies are currently investing in the United States - investments that drive groundbreaking research and create high-paying jobs. Instead, we support voluntary, market-based arrangements that foster collaboration and preserve the innovation ecosystem that has made America a global leader in medical advancements. We urge the Administration to carefully reconsider and reject these harmful proposals and focus on market-driven solutions that protect patients, jobs, and the economy."

###